Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVRD Tvardi Therapeutics Inc

交易中 03-23 12:23:33 EDT

3.70

+0.18

+5.09%

最高3.75	最低3.46	成交量1.98万
今开3.60	昨收3.52	日振幅8.15%
总市值3,470万	流通市值2,878万	总股本938.13万
成交额7.14万	换手率0.25%	流通股本777.87万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.6993,"timestamp":1774282685789,"preClose":3.52,"halted":0,"volume":19783,"delay":0,"changeRate":0.050937500000000004,"floatShares":7778729,"shares":9381344,"eps":-7.87,"marketStatus":"交易中","change":0.1793,"latestTime":"03-23 12:23:33 EDT","open":3.6,"high":3.75,"low":3.463,"amount":71357.0376691,"amplitude":0.081534,"askPrice":3.69,"askSize":10,"bidPrice":3.61,"bidSize":28,"shortable":3,"etf":0,"ttmEps":-7.87,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":3.52,"preHourTrading":{"tag":"盘前","latestPrice":3.4054,"preClose":3.52,"latestTime":"08:00 EDT","volume":67,"amount":228.16180000000003,"timestamp":1774267206153,"change":-0.1146,"changeRate":-0.032557,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.52,"preClose":3.52,"latestTime":"18:04 EDT","volume":18758,"amount":66025.352,"timestamp":1774044251590,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.71368,"impliedVol":2.1295,"impliedVolPercentile":0.5746},"requestUrl":"/m/hq/s/TVRD","defaultTab":"news","newsList":[{"id":"1153510288","title":"Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153510288?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:13","pubTimestamp":1767878002,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布，其新一代STAT3抑制剂Tti-109的一期临床试验取得重要进展。针对健康志愿者的顶线数据收集工作正按计划推进，预计将于2026年上半年完成。\n该研究旨在评估Tti-109的安全性、耐受性及药代动力学特征。STAT3作为关键信号传导蛋白，在多种肿瘤生长中扮演核心角色。Tti-109通过精准抑制STAT3活性，为晚期癌症治疗提供了新思路。\n目前临床试验进程符合预期时间表。若数据结果达到预设终点，将为后续针对实体瘤和血液恶性肿瘤的二期研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1175189763","title":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌（HCC）二期试验中的主要数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1175189763","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175189763?lang=zh_cn&edition=full","pubTime":"2025-11-14 05:26","pubTimestamp":1763069193,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌（HCC）二期试验中的主要数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1133823913","title":"Tvardi Therapeutics Inc：Piper Sandler将评级从增持下调至中性，目标价从78美元下调至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133823913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133823913?lang=zh_cn&edition=full","pubTime":"2025-10-13 22:06","pubTimestamp":1760364390,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc：Piper Sandler将评级从增持下调至中性，目标价从78美元下调至4美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1177816248","title":"Tvardi Therapeutics股价盘前暴跌66.3%，特发性肺纤维化试验未达预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1177816248","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177816248?lang=zh_cn&edition=full","pubTime":"2025-10-13 19:49","pubTimestamp":1760356154,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics股价在盘前交易中大跌66.3%，该公司的特发性肺纤维化治疗试验未能实现预设目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1154998252","title":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1154998252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154998252?lang=zh_cn&edition=full","pubTime":"2025-10-13 19:30","pubTimestamp":1760355014,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.102},{"period":"1month","weight":-0.0222},{"period":"3month","weight":-0.1156},{"period":"6month","weight":-0.9079},{"period":"1year","weight":-0.7722},{"period":"ytd","weight":-0.1814}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tvardi Therapeutics, Inc.于2017年12月20日注册成立，是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于开发针对STAT3的新型口服小分子疗法，以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解，该公司设计了一种创新方法来直接抑制STAT3，这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识，该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段，用于治疗纤维化驱动的疾病，初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032141},{"month":2,"riseRate":0.384615,"avgChangeRate":0.018638},{"month":3,"riseRate":0.538462,"avgChangeRate":0.011082},{"month":4,"riseRate":0.25,"avgChangeRate":-0.048535},{"month":5,"riseRate":0.583333,"avgChangeRate":0.009735},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.017433},{"month":7,"riseRate":0.5,"avgChangeRate":0.091173},{"month":8,"riseRate":0.5,"avgChangeRate":0.010865},{"month":9,"riseRate":0.25,"avgChangeRate":-0.036951},{"month":10,"riseRate":0.5,"avgChangeRate":-0.10272},{"month":11,"riseRate":0.5,"avgChangeRate":0.037928},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016361}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tvardi Therapeutics Inc,TVRD,Tvardi Therapeutics Inc股票,Tvardi Therapeutics Inc股票老虎,Tvardi Therapeutics Inc股票老虎国际,Tvardi Therapeutics Inc行情,Tvardi Therapeutics Inc股票行情,Tvardi Therapeutics Inc股价,Tvardi Therapeutics Inc股市,Tvardi Therapeutics Inc股票价格,Tvardi Therapeutics Inc股票交易,Tvardi Therapeutics Inc股票购买,Tvardi Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}